Lyra Therapeutics, Inc. LYRA
Set alert
At close · Oct 29
After hours · Oct 29, 4:00 PM ET
- YTD
- -93.83%
- 1 year
- -96.74%
- Open
- 0.4501
- Prev close
- 0.19
- Mkt cap
- 337.23K
- Vol
- 5.47K
- Avg vol
- 907
- EPS
- -18.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3623
- High
- 0.52
- Forward P/E
- -0.24
- Beta
- -0.04
- Short ratio
- 0.89
- Inst. own
- 59.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.2216
- 200-d avg
- 1.32
- 1y target
- 1.25
News
2 weeks ago defenseworld.net
Lyra Therapeutics (OTCMKTS:LYRA) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Analysis
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago defenseworld.net
ARS Pharmaceuticals (NASDAQ:SPRY) vs. Lyra Therapeutics (OTCMKTS:LYRA) Head to Head Review
Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
1 month ago defenseworld.net
Head to Head Contrast: Lyra Therapeutics (OTCMKTS:LYRA) versus Cronos Group (NASDAQ:CRON)
Cronos Group (NASDAQ: CRON - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the…
1 month ago defenseworld.net
Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the…
6 months ago globenewswire.com
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S.…
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
9 months ago benzinga.com
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
9 months ago benzinga.com
US Stocks Lower; Dow Tumbles Over 250 Points
US Stocks Lower; Dow Tumbles Over 250 Points
9 months ago globenewswire.com
Lyra Therapeutics Provides Corporate Update
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further…
10 months ago defenseworld.net
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 0.3% – Time to Buy?
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 0.3% on Friday. The stock traded as high as $3.70 and last traded at $3.59. Approximately 32,339 shares changed hands…
11 months ago defenseworld.net
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 4.5% – Should You Buy?
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 4.5% on Wednesday. The stock traded as high as $4.32 and last traded at $4.19. Approximately 48,758 shares traded hands…
11 months ago zacks.com
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $5.98. This compares to a loss of $9 per share a year ago.
11 months ago globenewswire.com
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago globenewswire.com
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06,…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago zacks.com
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago.
1 year ago globenewswire.com
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for…
1 year ago globenewswire.com
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of…
1 year ago seekingalpha.com
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3,…
1 year ago zacks.com
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
1 year ago zacks.com
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
1 year ago finbold.com
This penny stock just spiked 550% in a day; Time to buy?
Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.
1 year ago benzinga.com
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
3 years ago benzinga.com
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 89 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday saw 196 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 138 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
-
4 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
4 years ago benzinga.com
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For March 9, 2021
Companies Reporting Before The Bell • Barnes & Noble Education (NYSE:BNED) is expected to report quarterly loss at $0.38 per share on revenue of $397.48 million.
-
5 years ago benzinga.com
78 Biggest Movers From Yesterday
Gainers Obalon Therapeutics, Inc. (NASDAQ: OBLN) shares climbed 115% to close at $2.30 on Monday after declining around 5% on Friday.
-
5 years ago benzinga.com
54 Stocks Moving In Monday's Mid-Day Session
Gainers Obalon Therapeutics, Inc. (NASDAQ: OBLN) shares jumped 115.9% to $2.31 after declining around 5% on Friday.